Exploration on the mechanism related to the treatment of allergic rhinitis rats with Xinyi Powder based on transient receptor potential vanilloid subfamily 1 pathway
Objective:To investigate the efficacy and mechanism of action of Xinyi Powder based on transient receptor potential vanilloid subfamily 1(TRPV1)pathway in the treatment of allergic rhinitis(AR)rats.Methods:A total of 70 SD rats were randomly divided into the blank group,the model group,the low,medium and high dose groups of Xinyi Powder,the agonist group and the positive drug group,with 10 rats in each group.Except for the blank group,all the rats in each group were sensitized by ovalbumin(OVA)to create a rat model of AR.After successful modeling,corresponding drugs for treatment was gaved and sensitization was maintained by OVA nasal drops in all groups except the blank group.Behavioral scores were observed before and after treatment,and morphological changes of nasal mucosa tissue were observed by HE staining;serum IL-4,IL-5,IL-13,IgE levels were detected by ELISA;TRPV1,SP,CGRP,NGF levels in nasal mucosa tissue were detected by ELISA.Results:Compared with the blank group,the model group showed increased expression of IgE,IL-4,IL-5,IL-13 in peripheral blood(P<0.01),and TRPV1,SP,CGRP,NGF in nasal mucosa(P<0.01);compared with the model group,the three dose groups decreased expression of IgE,IL-4,IL-5,IL-13 in peripheral blood(P<0.05,P<0.01),and TRPV1,SP,CGRP,and NGF in nasal mucosa(P<0.01);compared with the positive drug group and the agonist group,there was a statistically increase in peripheral blood IgE,IL-4,IL-5,IL-13 expression in the medium dose group of Xinyi Powder(P<0.01),and increase in nasal mucosal TRPV1,SP,CGRP,and NGF expression in the medium dose group of Xinyi Powder(P<0.01).Conclusion:Xinyi Powder may reduce the release of SP,CGRP and IL-4 by modulating the TRPV1 pathway thereby inhibiting the overactivation of Th2 cells,decreasing itch nerve sensitization,relieving nasal itch,and treating AR.